Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 04/12/2024 GMT			5-day change	1st Jan Change
91.59 ^USD	-0.97%		-0.89%	+13.06%

05:40pm	Gilead Sciences, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 11:40 AM
03:26pm	HSBC Adjusts Price Target on Gilead Sciences to $82 From $69	MT

Evolution of the Average Target: Gilead Sciences, Inc.

average-target-price-chart GILEAD-SCIENCES-INC

Evolution of the Target Price: Gilead Sciences, Inc.

target-price-consensus-chart GILEAD-SCIENCES-INC

Changes in Analyst Recommendations: Gilead Sciences, Inc.

4c2a3e22ae82c38d6f47722174.uVHxWMWSCELHKpYsL-lOK8NqhEo3xI7wp8H2CdFIVxY._mfCGozxYyvxB_FmG4V7ZKkg4D4HgvaUw4qDWZYZLlCUHLMyis14cq1a_Q~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

HSBC Adjusts Price Target on Gilead Sciences to $82 From $69	02:26pm	MT
Jefferies Raises Price Target on Gilead Sciences to $115 From $105	12-02	MT
UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating	11-22	MT
Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90	11-20	MT
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73	11-18	MT
RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81	11-18	MT
Wolfe Research Initiates Gilead Sciences at Outperform With $110 Price Target	11-15	MT
Maxim Downgrades Gilead Sciences to Hold From Buy	11-08	MT
Truist Securities Raises Price Target on Gilead Sciences to $97 From $83, Maintains Hold Rating	11-08	MT
Raymond James Adjusts Gilead Sciences Price Target to $103 From $95, Maintains Outperform Rating	11-07	MT
JPMorgan Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating	11-07	MT
Barclays Adjusts Price Target on Gilead Sciences to $95 From $84, Maintains Equalweight Rating	11-07	MT
TD Cowen Adjusts Price Target on Gilead Sciences to $95 From $85, Maintains Buy Rating	11-07	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $102 From $94, Maintains Outperform Rating	11-07	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Outperform Rating	11-07	MT
Piper Sandler Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Overweight Rating	11-07	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating	11-07	MT
RBC Capital Adjusts Price Target on Gilead Sciences to $81 From $75, Maintains Sector Perform Rating	11-07	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $84 From $74, Maintains Neutral Rating	11-07	MT
Baird Raises Price Target on Gilead Sciences to $95 From $80, Maintains Neutral Rating	11-07	MT
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $80 From $70, Maintains Neutral Rating	11-07	MT
Jefferies Adjusts Gilead Sciences Price Target to $105 From $95	11-04	MT
Leerink Partners Upgrades Gilead Sciences to Outperform, Price Target is $96	10-21	MT
Leerink Partners Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $96	10-21	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $94 From $85	10-17	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	GILEAD SCIENCES, INC.					+5.57%
	ELI LILLY AND COMPANY					+22.07%
	NOVO NORDISK A/S					+20.41%
	JOHNSON & JOHNSON					+14.79%
	ABBVIE INC.					+12.66%
	MERCK & CO., INC.					+27.96%
	ROCHE HOLDING AG					+19.20%
	ASTRAZENECA PLC					+30.32%
	NOVARTIS AG					+10.23%
	AMGEN INC.					+17.99%
	Average					+18.12%
	Weighted average by Cap.					+19.18%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

92.49USD

Average target price

97.85USD

Spread / Average Target

+5.79%

High Price Target

125.00USD

Spread / Highest target

+35.15%

Low Price Target

73.00USD

Spread / Lowest Target

-21.07%

Analyst Consensus Detail

consensus-detail-chart GILEAD-SCIENCES-INC

Consensus revision (last 18 months)

consensus-revision-chart GILEAD-SCIENCES-INC

Analysts covering the company

Jefferies & Co.
UBS
Mizuho Securities
Daiwa Securities
RBC Capital Markets
Wolfe Research
Maxim
Truist Securities
Goldman Sachs
Raymond James
JPMorgan Chase
Barclays
TD Cowen
BMO Capital
Oppenheimer
Piper Sandler
Wells Fargo Securities
Baird
Cantor Fitzgerald
Leerink Partners
Morgan Stanley
Redburn Atlantic
Deutsche Bank Securities
HSBC
Argus
BofA Securities
SVB Securities LLC
Cowen
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK	Elmar Kraus